A chemical component of the marijuana plant could prevent the onset of pain associated with drugs used in chemo therapy, particularly in breast cancer patients, according to researchers at Temple University’s School of Pharmacy.
The researchers developed animal models and tested the ability of the compound cannabidiol, which is the second most abundant chemical found in the marijuana plant, to relieve chemo-induced neuropathic pain, said Sara Jane Ward, research assistant professor of pharmaceutical sciences in Temple’s School of Pharmacy and the study’s lead author.
“We found that cannabidiol completely prevented the onset of the neuropathic, or nerve pain caused by the chemo drug Paclitaxel, which is used to treat breast cancer,” said Ward, who is also a research associate professor in Temple’s Center for Substance Abuse Research.
Ward said that one of cannabidiol’s major benefits is that, unlike other chemicals found in marijuana such as THC, it does not produce psycho-active effects such as euphoria, increased appetite or cognitive deficits. “Cannabidiol has the therapeutic qualities of marijuana but not the side effects,” she said.
Ward’s research has long focused on systems in the brain that are impacted by marijuana and whether those systems could be targeted in the treatment of various disorders. “Marijuana binds to the cannabinoid receptors in the body and researchers have long been interested in whether there is therapeutic potential for targeting this receptor system,” she said.
Ward became interested in this current study after attending a conference in which she learned about a pain state that is induced by chemo-therapeutic agents, especially those used to treat breast cancer, which can produce really debilitating neuropathic pain.
Cannabidiol has also demonstrated the ability to decrease tumor activity
in animal models, said Ward, which could make it an effective
therapeutic for breast cancer, especially if you “combined it with a
chemo agent like Paclitaxel, which we already know works well.”
According to Ward, there are currently about 10 clinical trials underway
in the United States for cannabidiol on a range of different disorders,
including cannabis dependence, eating disorders and schizophrenia.
Because of this, she believes it will be easier to establish a clinical
trial for cannabidiol as a therapeutic against neuropathic pain
associated with chemo drugs.
In addition to Ward, Temple researchers involved in the study included
Michael David Ramirez, Harshini Neelakantan and Ellen Ann Walker. The
study was supported by grants from the National Institutes of Health and
the Peter F. McManus Charitable Trust.This article was first published at www.newswise.com